Radiation Oncology


Questions discussed in this category

The FDA recently approved neratinib based on data from the ExteNET trial; however, benefit appears modest and the risk of toxicity is not low.

Papers discussed in this category

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006-09-01